Aim immunotech and study collaborator roswell park commence enrollment in an nci-funded phase 2 clinical trial evaluating ampligen® (rintatolimod) in primary pd-1/pd-l1 resistant melanoma

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, ampligen and celecoxib for the treatment of hla-a2+ refractory melanoma

AIM Ratings Summary

AIM Quant Ranking